Claims for Patent: 6,316,408

✉ Email this page to a colleague

Summary for Patent: 6,316,408

Title:	Methods of use for osetoprotegerin binding protein receptors
Abstract:	A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget\'s disease are also provided. Receptors for osteoprotegerin binding proteins are also described. The receptors, and agonists and antagonists thereof, may be used to treat bone diseases.
Inventor(s):	Boyle; William J. (Moorpark, CA)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	09/052,521
Patent Claims:	1. A method for preventing or treating bone disease in a mammal comprising administering to a mammal having reduced bone density or susceptible to reduced bone density a therapeutically effective amount of a soluble form of an osteoclast differentiation and activation receptor (ODAR). 2. The method of claim 1 wherein ODAR comprises a soluble form of human ODAR. 3. The method of claim 2 wherein the soluble form of human ODAR is lacking a functional transmembrane region. 4. The method of claim 2 wherein ODAR comprises part or all of the extracellular domain of human ODAR and is capable of binding to OPG binding protein. 5. The method of claim 2 wherein the soluble form of human ODAR is fused to a heterologous amino acid sequence. 6. The method of claim 5 wherein the heterologous amino acid sequence comprises an Fc region of human IgG. 7. The method of claim 1 wherein the mammal is a human. 8. The method of claim 1 wherein the bone disease is selected from the group consisting of osteoporosis, osteomyelitis, hypercalcemia of malignancy, osteopenia brought on by surgery or steroid administration, Paget's disease, osteonecrosis, bone loss due to rheumatoid arthritis, periodontal bone loss, immobilization, prosthetic loosening and osteolytic metastasis. 9. The method of claim 1 further comprising administering a therapeutically effective amount of a bone morphogenic factor, TGF-.beta. family member, fibroblast growth factor, IL-1 inhibitor, TNF-.alpha. inhibitor, parathyroid hormone, E series prostaglandin, bisphoshponate, estrogen, SERM, or bone-enhancing mineral.

Details for Patent 6,316,408

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Takeda Pharmaceuticals U.s.a., Inc.	NATPARA	parathyroid hormone	For Injection	125511	January 23, 2015	⤷ Subscribe	2017-04-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.